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Abstract Autopsy after transcatheter aortic valve implanta-
tion (TAVI) is a new field of interest in cardiovascular pathol-
ogy. To identify the cause of death, it is important to be famil-
iar with specific findings related to the time interval between
the procedure and death. We aimed to provide an overview of
the autopsy findings in patients with TAVI in their medical
history divided by the timing of death with specific interest in
the added value of autopsy over a solely clinically determined
cause of death. In 8 European centres, 72 cases with autopsy
reports were available. Autopsies were divided according to
the time interval of death and reports were analysed. In 32
patients who died ≤72 h postprocedure, mortality resulted
from cardiogenic or haemorrhagic shock in 62.5 and 34.4%,
respectively. In 31 patients with mortality >72 h to ≤30 days,
cardiogenic shock was the cause of death in 51.6% followed
by sepsis (22.6%) and respiratory failure (9.7%). Of the nine
patients with death >30 days, 88.9% died of sepsis, caused by
infective endocarditis in half of them. At total of 12 patients
revealed cerebrovascular complications. Autopsy revealed un-
expected findings in 61.1% and resulted in a partly or
completely different cause of death as was clinically deter-
mined. Autopsy on patients who underwent TAVI reveals spe-
cific patterns of cardiovascular pathology that clearly relate to
the time interval between TAVI and death and significantly
adds to the clinical diagnosis. Our data support the role of
autopsy including investigation of the cerebrum in the quickly
evolving era of cardiac device technology.
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Introduction
Aortic valve stenosis is the most common valvular heart dis-
ease in adults and has a strong age associated incidence [4]. As
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a result of increasing life expectancies, the prevalence of the
disease increases simultaneously [3]. For patients considered
to be at high or prohibitive risk for conventional cardiac sur-
gery, transcatheter aortic valve implantation (TAVI) evolved
as an alternative, less invasive treatment [1, 7, 12]. In TAVI, no
sternotomy is necessary and the aortic valve is not excised;
instead, a catheter is used to implant a bioprosthetic valve over
the native valve. Over the past decade, the increased preva-
lence of aortic valve stenosis combined with improvements in
material, experience and techniques resulted in an expanding
number of TAVI procedures.
The TAVI population is relatively old and has complex
comorbidities inhibiting conventional surgery. The report-
ed 1-year mortality after TAVI ranges from 14 to 31% [1, 9,
18], and the novelty of the procedure creates a new field of
interest in cardiovascular autopsy pathology. Since the
number of patients treated with TAVI increases, a rise in
submissions in autopsy practice is expected. However, cur-
rent literature reviewing the causes of death at autopsy
after TAVI is scarce and consists of small single-centre
case series [8, 9]. Moreover, clinicians may waive the op-
tion of autopsy in this elderly population since it is not
known what the added value of autopsy after TAVI is. To
identify the cause of death in this population with signifi-
cant comorbidities, it is important to be familiar with the
specific procedure-related findings at autopsy. We
hypothesise that the findings at autopsy after TAVI will
differ substantially according to the time interval of death
after the procedure. Therefore, we provide an overview of
autopsy findings after TAVI procedures in multiple centres
with specific expertise in cardiovascular pathology and
emphasise the timing of death after the procedure. In addi-
tion, we consider the added value of an autopsy for deter-
mination of the cause of death by comparing the pathologic
findings at autopsy with the clinically determined cause of
death.
Methods
For this observational retrospective study, institutional au-
topsy registries of eight European pathology laboratories
with specific cardiovascular expertise were screened for
patients with TAVI in their medical history. Registries of
the following laboratories were screened: Academic
Medical Centre Amsterdam, VU Medical Centre
Amsterdam, Erasmus Medical Centre Rotterdam, Sint
Antonius Nieuwegein, Deutsches Herzzentrum Berlin, St.
George Hospital Medical School London, Cardiovascular
Pathology Unit University of Padua and the Pisa
University Hospital. Autopsies were performed according
to local legislation. All available autopsy reports of these
hospitals were included in our analysis. A standardised
questionnaire was used to evaluate the autopsy reports
and archived tissues (heart specimens and/or paraffin
blocks). The following information was required for the
questionnaire: baseline and procedural characteristics, the
clinically suspected cause of death and the primary cause
of death found at autopsy, specific findings of cardiac au-
topsy (cardiac hypertrophy and/or dilatation, native valve
abnormalities, pathology of the aortic root, signs of ische-
mic heart disease, positioning of the implanted prosthesis,
signs of valvular thrombosis or endocarditis, procedure-
related trauma) and findings at cerebral autopsy.
In order to divide the autopsies in time intervals of death,
we used the standardised endpoints of the VARC-2 recom-
mendations [8]. We distinguished cases with immediate pro-
cedural mortality (≤72 h postprocedure), procedural mortality
(>72 h to ≤30 days postprocedure) and postprocedural mor-
tality (>30 days postprocedure).
Results
In the 8 participating centres, 72 cases of autopsy after
TAVI were available. Procedures were performed between
2007 and 2015 with the self-expandable Medtronic
CoreValve (Medtronic Inc., Minneapolis, MN, USA), the
balloon expandable Edwards SAPIEN/SAPIEN XT/Sapien
3 (Edwards Life Sciences LCC, Irvine, CA, USA) or the
Lotus (Boston Scientific Corporation, Marlborough, MA,
USA) bioprostheses. Reported access routes were
transfemoral (n = 29), transapical (n = 28), transaortic
(n = 5) and subclavian (n = 2) (not documented, n = 8).
Eleven procedures were performed under conscious seda-
tion with local analgesia (15.3%), all other under general
anaesthesia. In seven patients, the performed TAVI was
superimposed on a previously surgically inserted
degenerated aortic valve prosthesis (n = 6) or a not correct-
ly positioned transcatheter prosthesis (n = 1) (‘valve-in-
valve procedures’, 9.7%). Baseline characteristics of all
patients divided per time interval of death and general find-
ings at autopsy are presented in Table 1. In all but one case
(98.6%), a pre-existent damaged heart was found, with
hypertrophy and/or dilatation and scarring fibrosis due to
previous infarctions. In 52 patients, 72.2% cerebral autop-
sy was performed in addition to the cardiac autopsy.
Immediate procedural mortality (≤72 h postprocedure)
A total of 32 patients died within 72 h of the procedure
(44.4% of the total cohort) of whom 19 patients died on the
day of the TAVI. In three patients, no prosthesis was im-
planted since death occurred in an early phase of the pro-
cedure. The clinically suspected causes of death are de-
scribed in Table 2. Death due to cardiogenic shock was
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clinically suspected in most patients, 22 of the 32 (68.8%).
The primary causes of death found at autopsy are described
in Table 3. In 20 of the 32 patients (62.5%), the primary
cause of death was a cardiogenic shock due to cardiac
hypertrophy and dilatation (end-stage cardiac failure),
within addition signs of acute ischemia in 10 of these 20
patients. In these cases, the procedure was interpreted as
the eliciting factor of death. In one patient, a large hema-
toma in the right atrial wall was found; histological exam-
ination revealed recent bleeding in proximity to the AV
node and myocardial ischemia. Haemorrhagic shock was
observed as the primary cause of death in 11 patients
(34.4%), mostly as a consequence of aortic annulus rup-
ture. Although brain autopsy revealed signs of a cerebro-
vascular accident in three patients (Table 1), in only one
patient, the primary cause of death was described to be due
to an ischemic stroke caused by thromboembolic occlusion
of the basilar artery. Histological analysis revealed that the
thrombotic material originated from a thrombus mass at the
prosthesis site. Infectious disease was not observed in pa-
tients who died within 72 h postprocedure (Tables 1 and 4).
Procedural mortality (>72 h to ≤30 days postprocedure)
Thirty-one patients died between 72 h and 30 days after the
procedure (43.1% of the total cohort) after a mean of
12 days after TAVI (Table 1). The clinically suspected
cause of death was cardiogenic in 14 patients (45.2%),
followed by sepsis in 6 patients (19.4%) (Table 2). The
primary causes of death found at autopsy are described in
Table 3. The leading cause was of cardiogenic origin in 16
patients (51.6%). Thirteen patients died due to cardiac hy-
pertrophy and dilatation (end-stage cardiac failure), with or
without signs of acute myocardial ischemia. In one of the
patients with ischemia, the prosthesis was implanted too
high, obstructing the coronary ostia. In addition, two pa-
tients had worsening of heart failure due to severe mitral
regurgitation caused by obstruction of the mitral leaflets by
a too low implanted prosthesis. In another patient, the pros-
thesis pressed on the cardiac septum, damaging the con-
duction system. Two patients died of haemorrhagic shock
(6.5%) and seven of sepsis with multiorgan failure
(22.6%). In two of the patients with sepsis, thrombotic
Table 1 Baseline characteristics
and general autopsy findings at
time of autopsy per time interval
of death
Characteristics ≤72 h, n = 32 >72 h to ≤30 days, n = 31 >30 days, n = 9
Female 19 (59.4%) 16 (51.6%) 3 (33.3%)
Age 80 (±5) 79 (±8) 82 (±8)
Body mass index 27.2 (±8.9) 25.5 (±13.6) 29.0 (±4.9)
Medical history
Hypertension 24 (75.0%) 19 (61.3%) 7 (77.8%)
Hypercholesterolemia 14 (43.8%) 12 (38.7%) 6 (66.7%)
Diabetes 16 (50.0%) 11 (35.5%) 1 (11.1%)
Atrial fibrillation 12 (37.5%) 15 (48.4%) 5 (55.6%)
Stroke 2 (6.2%) 6 (19.4%) 0 (0.0%)
CABG 13 (40.6%) 9 (29.0%) 3 (33.3%)
PCI 12 (37.5%) 11 (35.5%) 1 (11.1%)
Heart weight 584.9 (±148.0) 569.9 (±116.3) 602.4 (±196.6)
Cardiac hypertrophy 28 (87.5%) 28 (90.3%) 9 (100%)
Cardiac dilatation 14 (43.8%) 12 (38.7%) 5 (55.6%)
Old myocardial infarction 22 (68.8%) 18 (58.1%) 4 (44.4%)
Recent myocardial infarction 12 (37.5%) 12 (38.7%) 2 (22.2%)
Procedure-related haemorrhage 11 (34.4%) 2 (6.5%) –
Not correctly positioned prosthesis 1 (3.1%) 5 (16.1%) 1 (11.1%)
Thrombus at prosthesis site 1 (3.1%) 3 (9.7%) 1 (11.1%)
Cerebrovascular accident 3 (9.4%) 7 (22.6%) 2 (22.2%)
Ischemic 3 (9.4%) 6 (19.4%) 2 (22.2%)
Haemorrhage 2 (6.3%) 3 (9.7%) –
Microbleeds 1 (3.1%) 4 (12.9%) –
Endocarditis – (0.0%) 1 (3.2%) 4 (44.4%)
Sepsis – (0.0%) 8 (25.8%) 8 (88.9%)
Dichotomous data are presented as number of patients (%); continuous data are expressed as mean (±SD)
CABG coronary artery bypass graft, PCI percutaneous coronary intervention
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material was found at the site of implantation (one patient
with candida sepsis whom had multiple abscesses in the
myocardium and one patient with ischemic colitis). Acute
respiratory distress syndrome (ARDS) leading to respira-
tory failure was the cause of death in three patients (9.7%).
Although signs of a cerebrovascular accident were found
in seven patients (Table 1), only in two patients a cerebral
infarct was described as the primary cause of death (6.5%)
(Table 3). One of these patients also had extensive infec-
tious endocarditis of the TAVI prosthesis with thrombus at
the prosthesis site and myocarditis. In one patient with a
low inserted prosthesis, cerebral oedema with herniation of
the cerebellar tonsils was interpreted as primary cause of
death.
Postprocedural mortality (>30 days postprocedure)
Nine patients died more than 30 days after TAVI (12.5%).
The time interval between TAVI and onset of death ranged
from 33 to 936 days. Septic shock was the most frequent
clinically suspected cause of death (Table 2). Sepsis was
also the leading cause of death at autopsy (the major
pathological finding in eight patients; Table 3). In four
patients, sepsis was a consequence of infective endocar-
ditis; two of them died within 2 months and two after
2 years. In a patient who died of sepsis caused by pneu-
monia, a too low implanted prosthesis was found,
obstructing the mitral valve but not directly leading to
death. Although not defined as the main cause of death,
in two patients, signs of a cerebrovascular accident were
found (Table 1). These cerebral infarcts originated from
septic embolisms after endocarditis and ischemic colitis,
respectively.
Correlation of clinically suspected cause of death
and cause of death at autopsy
In 28 of the 72 patients, the clinically determined cause of
death was confirmed as the primary cause of death at autopsy
(38.9%). In 44 patients, autopsy revealed relevant additional
findings (61.1%) that resulted in a partly or completely differ-
ent cause of death as was determined clinically (34.7 and
26.4%, respectively). In patients with mortality between
72 h and 30 days, the discrepancy between the clinically
Table 2 Clinical suspected
causes of death per time interval Cause of death ≤72 h, n = 32 >72 h to ≤30 days, n = 31 >30 days, n = 9
Cardiogenic shock 22 (68.8%) 14 (45.2%) 0
Electromechanical dissociation 9 1 –
Acute myocardial infarction 5 2 –
Acute worsening heart failure 3 8 –
Unknown cause 5 3 –
Hemorrhagic shock 7 (21.9%) 4 (12.9%) 0
Annular rupture 2 – –
Retroperitoneal hematoma 1 1 –
Pericardial perforation 1 – –
Gastrointestinal – 2 –
Unknown origin 3 1 –
Sepsis 0 6 (19.4%) 7 (77.8%)
Origin endocarditis – 1 1
Origin infected feet – – 1
Origin pneumonia – 2
Origin cellulitis – 1
Sepsis unknown origin – 5 1
Respiratory failure 1 (3.1%) 2 (6.5%) 0
Cerebral infarction 2 (6.3%) 3 (9.7%) 0
Basilar artery 2 1 –
Left middle cerebral artery – 1 –
Diffuse – 1 –
Multiorgan failure unknown origin 0 1 (3.2%) 0
Renal insufficiency 0 1 (3.2%) 0
Malignancy 0 0 1 (11.1%)
Unknown cause 0 0 1 (11.1%)
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suspected cause of death and the cause of death at autopsy was
highest as the clinically suspected cause was only confirmed
in 9 of the 31 patients (29.0%). The correlation per category of
the suspected cause of death is described in Table 4.
Discussion
With an expanding number of TAVI procedures worldwide,
pathologists will be exposed more often to autopsies of pa-
tients with TAVI in their medical history. This study is the
largest and only international multicentre study on autopsy
findings in this relatively new patient population. We found
different patterns of the causes of death amongst the different
time intervals between the procedure and death and also dem-
onstrated a substantial additional value of autopsy to the solely
clinical determined cause of death. Previous reports on autop-
sy after TAVI are limited to small single-centre analysis of
autopsies in 13 or 17 cases and did not focus on discrepancies
between clinically determined causes of death and the subse-
quently derived findings at autopsy [10, 15].
Cardiac pathology in relation to the time interval
after TAVI
TAVI is the preferred therapy for patients with high or prohib-
itive risk for surgery. TAVI patients are relatively old and have
an extensive medical history, the pathologist should be aware
of. This was also seen in our population, with a mean age of
80 years and a high incidence of co-morbidities including
cardiovascular risk factors and an overrepresentation of previ-
ous coronary procedures. As could be expected in patients
with (a history of) aortic valve stenosis, findings of cardiac
hypertrophy and dilatation and evidence of old ischemia were
noted at autopsy in nearly all patients.
It appeared of pivotal importance to aim attention at the
time interval between the TAVI procedure and death.
Cardiogenic and especially haemorrhagic shock occurred less
Table 3 Primary causes of death at autopsy per time interval of death
Cause of death ≤72 h, n = 32 >72 h to ≤30 days, n = 31 >30 days, n = 9
Cardiogenic shock 20 (62.5%) 16 (51.6%) 1 (11.1%)
End-stage cardiac failure with recent ischemia 10 6 1
End-stage cardiac failure without recent ischemia 9 7 –
Large hematoma AV node damaging conduction system with recent ischemia 1 – –
Mechanical obstruction mitral valve by TAVI prosthesis – 2 –
Right ventricular failure secondary to pulmonary embolisms – 1 –
Hemorrhagic shock 11 (34.4%) 2 (6.5%) 0
Annular rupture 5 – –
Retroperitoneal hematoma 1 1 –
Perforated pericardium by pacemaker wire in compromised heart 1 – –
Dissection thoracic aorta 1 – –
Anastomosis previous CABG 1 – –
Transmural tear aortic wall 1 – –
DIC 1 1 –
Sepsis 0 7 (22.6%) 8 (88.9%)
Cardiac origin endocarditis of TAVI prosthesis – – 4
Cardiac origin pacemaker wire – 1 –
Not (directly) cardiac origin pneumonia – 3 2
Not (directly) cardiac origin ischemic colitis – 1 1
Not (directly) cardiac origin necrotizing cholecystitis – 1 –
Not (directly) cardiac origin unknown, candida found – 1 –
Not (directly) cardiac origin cellulitis – 1
Respiratory failure—ARDS 0 3 (9.7%) 0
Cerebral infarction 1 (3.1%) 2 (6.5%) 0
Basilar artery 1 1 –
Left middle cerebral artery – 1 –
Cerebral edema 0 1 (3.2%) 0
ARDS acute respiratory distress syndrome, CABG coronary artery bypass graft, DIC diffuse intravascular coagulation
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frequently as time after the procedure passed. On the contrary,
respiratory failure and sepsis only occurred after 72 h.
Amongst patients who died after 72 h, a high incidence of
prosthetic valve endocarditis of 12.5% (5 of the 40 cases)
was present, which was even higher than the reported inci-
dence in literature of 3.1% in the first year after TAVI [16].
Furthermore, we demonstrated the importance of paying at-
tention to the position of the prosthesis at autopsy. Incorrect
positioned prosthesis could be related to conduction disorders,
severe mitral regurgitation or coronary obstruction [5, 11, 17].
The demonstration of damage of the conduction system by
histopathological analyses is difficult. In most patients, in this
study, a thorough examination of the conduction system was
not described. We suppose that systematic histopathological
investigation of the AV node and proximal bundle branches
would reveal a much higher incidence of haemorrhagic and or
ischemic changes at these specific sites.
TAVI and cerebral pathology
Cerebral infarcts are a well-known complication of TAVI with
a reported 30-day clinical stroke incidence of approximately
3–4% and the highest incidence within 24 h after the proce-
dure [2, 6, 14]. We found old and new ischemic or
haemorrhagic lesions in 12 of the 52 patients in whom cere-
bral autopsy was performed. This implies that, although not
always considered the primary cause of death, unexpected
cerebral lesions are found in a large proportion of the TAVI
population. Moreover, in two patients with a suspected cere-
bral infarct, no ischemic or haemorrhagic brain lesions were
found. Therefore, cerebral autopsy can be considered ex-
tremely helpful in determining the cause of death after
TAVI, and clinicians should be encouraged to ask for permis-
sion of the relatives for this type of autopsy.
A striking finding in our autopsies was the detection of
thrombus at the site of the prosthesis in five patients (6.9%).
Recently, Makkar et al. reported a high incidence of 13 to 40%
of reduced leaflet motion after implantation of a bioprosthetic
valve, identified on computed tomography (CT). This condi-
t ion resolved with administrat ion of therapeutic
anticoagulation, suggesting that reduced leaflet motion could
be associated with subclinical leaflet thrombosis [13]. In
agreement with the report of Makkar et al., we hypothesise
that although stroke after TAVI is multifactorial, valve throm-
bus with possible embolisation of thrombotic material may
play an important role in developing cerebral ischemic le-
sions. In an earlier reported series of thromboembolic events
after TAVI, we demonstrated the importance of removal of the
prosthesis from its location in the left ventricular outflow tract
for inspection on the presence of thrombus [20]. This is further
supported by the analysis in this current study; in three of the
five patients with prosthesis site thrombus, signs of ischemic
stroke were found.
Clinical diagnosis versus diagnosis at autopsy
We demonstrated that clinically relevant extra findings were
found at autopsy in 61.1% of the patients, which completely
changed the perception on the cause of death in 26.4% of all
patients. These large discrepancies highlight the vital impor-
tance of autopsy over a solely clinically determined cause of
death, not just in the immediate postprocedural period but also
later after TAVI. In addition to this benefit of autopsy in de-
termining the causes of death, Vogel et al. recently demon-
strated a possible added value of performing postmortem
computed tomography (angiography) (PMCT) after TAVI
[19]. The authors were able to show coronary artery disease
and position of the implanted device and demonstrated the
specific localisation of haemorrhage [19]. PMCT with angi-
ography could be considered valuable in addition to autopsy
to identify the cause of death after TAVI.
Table 4 Correlation clinical
suspected cause of death (COD)
and cause of death at autopsy
No. of patients
per category
clinical
suspected COD
COD autopsy
completely
same as clinically
suspected
COD autopsy
partly same as
clinically
suspected
COD autopsy
completely
differ from
clinically
suspected
Cardiogenic shock, n = 36 17 (47.2%) 12 (33.3%) 7 (19.4%)
Hemorrhagic shock, n = 11 5 (45.5%) 4 (36.4%) 2 (18.2%)
Sepsis, n = 13 3 (23.1%) 6 (46.2%) 4 (30.8%)
Respiratory failure, n = 3 2 (66.7%) – 1 (33.3%)
Cerebral infarction, n = 5 1 (20.0%) 3 (60.0%) 1 (20.0%)
Multiorgan failure, n = 1 – – 1 (100%)
Renal insufficiency, n = 1 – – 1 (100%)
Malignancy, n = 1 – – 1 (100%)
Unknown cause, n = 1 – – 1 (100%)
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Recommendations for autopsy
Based on the findings of our study, we propose a stepwise
approach to perform an autopsy after TAVI. Examples of spe-
cific findings at autopsy are demonstrated in Fig. 1. Obtaining
appropriate clinical information is essential before the heart is
removed from the thorax and should include technical aspects
of the procedure. Autopsy-related damage, especially at the
prosthesis site, should be avoided. Size and weight of the heart
provide information on underlying cardiac morbidity.
Attention should be paid to the type of prosthesis and the
position of the prosthesis in relation to the native valve, and
an X-ray could be helpful (Fig. 1). In case of a previous aortic
valve replacement, the position of the TAVI prosthesis in re-
lation to the (surgical) prosthetic valve should be assessed.
The implantation height and its relation to the ostia of the
coronary arteries as well as its relation to the mitral valve
should be determined. It is helpful to carefully inspect the
valve leaflets for thrombus and vegetation, including sampling
for histology and microbial culture. Especially if time has
passed between the TAVI procedure and death, it is advised
to sample valvar leaflets for features of tissue degeneration.
Inspection of in situ valvar (mal) alignment is important for
evaluation of paravalvular leakage. Except for cases with large
dehiscence, this inspection might be difficult. In patients with
late procedural mortality, the valve-bearing stent is encapsu-
lated and the presence of paravalvular leakage should be care-
fully evaluated with a probe. Thereafter, it is recommended to
remove the prosthesis to assess the landing zone in the left
ventricular outflow tract, sinus of Valsalva, native aortic valve
leaflets and coronary ostia for traumatic, thrombotic, calcific
and occlusive pathology. Nitro Blue Tetrazolium (NBT) stain
of a fresh myocardial slice at autopsy (to visualise early ische-
mic areas with LDH depletion) and histology of embedded
myocardial tissue provide information not only on the pres-
ence of myocardial infarction but also of the time of onset. In a
systematic examination of Koch’s triangle, the AV node area
is recommended for documentation of potential ischemia and
or haemorrhage. With the known high risk of cerebrovascular
events during and after TAVI, it is essential to perform cerebral
autopsy in all patients after a TAVI procedure.
Limitations
This study is a retrospective analysis of the autopsy findings
from eight different pathology laboratories. Although pathol-
ogists with cardiovascular pathology expertise performed all
autopsies, there was no standardised protocol. Therefore,
Fig. 1 Examples of two different
types of TAVI prosthesis. a
Postmortem X-ray of the heart
showing the result of TAVI with
CoreValve prosthesis in aortic
root position. Calcifications in
native aortic valve leaflets
(arrow) and in coronary arteries
and two pacemaker wires are also
visible. b CoreValve prosthesis,
6 weeks after implantation
showing overgrowth of stent
struts with intimal tissue. c
Ventricular view of same
CoreValve obstructed by large
vegetations attached to valvar
leaflets (arrow). Also note the
metal probe (arrowhead) in small
paravalvular leakage. d
Postmortem X-ray of the heart
with Edward Sapien TAVI
prosthesis. The stent bearing the
artificial valve of this type of
TAVI prosthesis is much smaller
than of the CoreValve (a). e
Example of mal-positioned
Edward Sapien prosthesis, with
significant protrusion of native
valve leaflet over prosthetic valve
leaflets
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autopsy techniques varied to some extent amongst the
institutes. Moreover, in the analysed cohort, the number
of autopsies after a transapical procedure was relatively
overrepresented since transfemoral procedures are usually
more common. Furthermore, we analysed 72 cases with
procedures from 2007 to 2015. Only a minority of less
than one fifth of the procedures was performed before
2010; however, during this wide range in time of the
procedure, some technical and procedural aspects for
TAVI changed. Newer generation prostheses may show
different complications if compared to older prostheses
due to changes frame heights and sheath size.
Since this is an elderly patient population, death without
autopsy is frequent, especially when it occurs out of hospital.
In addition, registries of all laboratories were screened for
patients with autopsy and a TAVI in their medical history. If
a TAVI was not clearly described in the medical history, these
patients were missed in our analysis. Therefore, this observa-
tional study does not consist of consecutive cases, and detailed
information on autopsy rates amongst the total population of
the patients who underwent TAVI and died in the different
institutes involved is lacking. Similarly, it is possible that au-
topsies were requested especially in those cases in which the
clinically suspected cause of death was not entirely clear. This
may induce an overestimation of the advantage of autopsy
over a solely clinically determined cause of death.
Conclusion
A structured autopsy, performed with knowledge of the gen-
eral medical history, the technique of the procedure and the
time of death in relation to the procedure, reveals valuable
information regarding the cause of death after TAVI. In addi-
tion to cardiac autopsy, cerebral autopsy is notably of added
value. Clinicians should appreciate autopsy over a solely clin-
ically determined cause of death. Pathologists performing
those autopsies should have knowledge of the procedure and
recognise the importance of the time interval between the
TAVI procedure and death.
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